HIV coreceptor phenotyping in the clinical setting

AIDS Reviews

Volumn 10, Issue 3, 2008, Pages 143-151

  Low, Andrew J ^a,b   Swenson, Luke C ^a,b   Harrigan, P Richard ^a,b  

^a BRITISH COLUMBIA CENTRE FOR EXCELLENCE IN HIV AIDS   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Coreceptor; HIV; Phenotype; Trofile; Tropism

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CXCR4; VIRUS RECEPTOR;

ANTIVIRAL RESISTANCE; DISEASE COURSE; DRUG DETERMINATION; DRUG TREATMENT FAILURE; FLOW CYTOMETRY; GENOTYPE PHENOTYPE CORRELATION; HETERODUPLEX ANALYSIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL DECISION MAKING; NONHUMAN; PREDICTION; RECEPTOR OCCUPANCY; REVIEW; SPECIES DIFFERENCE; TECHNOLOGY; TREATMENT OUTCOME;

ANTI-HIV AGENTS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; PHENOTYPE; REAGENT KITS, DIAGNOSTIC; RECEPTORS, CCR5; RECEPTORS, CXCR4; RECOMBINATION, GENETIC;

EID: 55049107630     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Sattentau Q. Moore J. Conformational changes induced in the HIV envelope glycoprotein by soluble CD4 binding. J Exp Med. 1991; 174:407-15.
2. Ashorn P, Berger E, Moss B. HIV envelope glycoprotein/CD4-mediated fusion of nonprimate cells with human cells. J Virol. 1990;64: 2149-56.
3. + T-cell lines vs. primary macrophages, Proc Natl Acad Sci USA. 1995;92: 9004-8.
4. Broder C, Dimitrov D, Blumenthal R, Berger E. The block to HIV-1 envelope glycoprotein-mediated membrane fusion in animal cells expressing human CD4 can be overcome by a human cell component(s). Virology. 1993;193:483-91.
5. Chesebro B, Buller R, Portis J, Wehrly K. Failure of HIV entry and infection in CD4-positive human brain and skin cells, J Virol. 1990; 64:215-21.
6. Clapham P, Blanc D, Weiss R, Specific cell surface requirements for the infection of CD4-positive cells by HIV types 1 and 2 and by SIV. Virology. 1991;181:703-15.
7. Dragic T, Charneau P, Clavel F, Alizon M. Complementation of murine cells for HIV envelope/CD4-mediated fusion in human/murine heterokaryons. J Virol. 1992;66:4794-802.
8. Dragic T, Picard L, Alizon M. Proteinase-resistant factors in human erythrocyte membranes mediate CD4-dependent fusion with cells expressing HIV-1 envelope glycoproteins. J Virol. 1995; 69:1013-18.
9. Harrington R, Geballe A. Cofactor requirement for HIV-1 entry into a CD4-expressing human cell line. J Virol. 1993;67:5939-47,
10. + T-cells. Science. 1995; 270:1811-15.
11. Feng Y, Broder C, Kennedy P, Berger E. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996:272:872-7.
12. Bleul C. Farzan M, Choe H, et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature, 1996; 382:829-33.
13. Oberlin E, Amara A. Bachelerie F, et al. The CXC chemolkine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1. Nature, 1996;382:833-5.
14. Collman R, Balliet J, Gregory S, et al, An infectious molecular clone of an unusual macrophage-tropic and highly cytopathic strain of HIV-1. J Virol. 1992;66:7517-21.
15. Platt E, Wehrly K, Kuhmann SE, Chesebro B, Kabat D. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophage tropic isolates of HIV-1. J Virol. 1998;72:2855-64.
16. Lee B, Sharron M, Montaner L, Weissman D, Doms R. Quantification of CD4, CCR5, and CXCR4 levels on lymphocyte subsets, dendritic cells, and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA. 1999;96:5215-20.
17. Tersmette M, de Goede R, Al B, et al. Differential syncytium-inducing capacity of HIV isolates: Frequent detection of syncytium-inducing isolates in patients with AIDS and AIDS-related complex. J Virol. 1988;62:2026-32.
18. Tersmette M. Gruters R, de Wolf F, et al. Evidence for a role of virulent HIV variants in the pathogenesis of AIDS: Studies on sequential HIV isolates. J Virol. 1989;63:2118-25.
19. Schuitemaker H. Kootstra N, de Goede R, de Wolf F, Miedema F, Tersmette M. Monocytotropic HIV-1 variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture. J Virol. 1991;65:356-63.
20. Koot M, Vos A, Keet R, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 co-cultivation assay. AIDS. 1992;6:49-54.
21. Boucher C, Lange J, Miedema F. et al. HIV-1 biological phenotype and the development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS. 1992; 6:1259-64.
22. Karlsson A, Parsmyr K, Sandstrom E, Fenyo E, Albert J, MT-2 cell tropism as prognostic marker for disease progression in HIV-1 infection. J Clin Microbiol. 1994;32:364-70.
23. Cheng-Mayer C. Seto D, Tateno M, Levy JA. Biologic features of HIV-1 that correlate with virulence in the host. Science. 1988; 240(4848):80-82
24. Tersmette M, Miedema F. Interactions between HIV and the host immune system in the pathogenesis of AIDS. AIDS. 1990;4(Suppl 1):S57-66.
25. Richman D, Bozzette S. The impact of the syncytium-inducing phenotype of HIV on disease progression. J Infect Dis. 1994;169:968-74.
26. Maas J, Gange S, Schuitemaker H, Coutinho R, van Leeuwen R, Margolick J. Strong association between failure of T-cell homeostasis and the syncytium-inducing phenotype among HIV-1-infected men in the Amsterdam cohort study. AIDS. 2000;14:1155-61.
27. Koot M, Keet I. Vos A. et al. Prognostic value of HIV-1 syncoum-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;118:681-8.
28. Schuitemaker H, Koot M, Kootstra N, et al. Biological phenotype of HIV-1 clones at different stages of infection: Progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol. 1992;66:1354-60.
29. Dong X, Chen X, Chen Y, et al. Short communication: HIV type 1 phenotype, tropism, and sequence patterns: Association and preference. AIDS Res Hum Retrovinuses. 2005;21:234-8.
30. Berkowitz R, Alexander S, Bare C, et al. CCR5- and CXCR4-utilizing strains of HIV-1 exhibit differential tropism and pathogenesis in vivo. J Virol. 1998;72:10108-17.
31. Trkola A. Ketas T. Kewalramani V, et al. Neutralization sensitivity of HIV-1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol. 1998;72:1876-85.
32. Coakley E, Petropoulos C, Whitcomb J. Assessing chemokine coreceptor usage in HIV. Curr Opin Infect Dis. 2005;18:9-15.
33. Whitcomb J, Huang W, Fransen S. et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine HIV-1 coreceptor tropism. Antimicrob Agents Chemother. 2007;51:566-75.
34. Trouplin V, Salvatori F, Cappello F, et al. Determination of coreceptor usage of HIV-1 from patient plasma samples by using a recombinant phenotypic assay. J Virol. 2001;75:251-9.
35. Gonzalez N, Perez-Olmeda M, Garcia-Perez J, et al. Evaluation of HIV-1 tropism using a new and sensitive system based on recombinant viruses. Antiviral Therapy. 2008; 13(Suppl 3):Al 19 [abstract].
36. Raymond S, Delobel P. Mavignier M, et al. Direct sequencing of V3 could be a valuable alternative to phenotypic assays for the routine assessment of HIV-1 tropism. Antiviral Therapy. 2008;13(Suppl 3):A114 [abstract].
37. Ping L, Nelson J, Hoffman I, et al. Characterization of V3 sequence heterogeneity in subtype C HIV-1 isolates from Malawi: Underrepresentation of X4 variants. J Virol. 1999;73:6271-81.
38. Huang W, Eshleman S, Toma J, et al. Coreceptor tropism in HIV-1 subtype D: high prevalence of CXCR4 tropism and heterogeneous composition of viral populations. J Virol. 2007;81:7885-93.
39. Whitcomb J, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine HIV-type 1 coreceptor tropism. Antimicrob Agents Chernother. 2007; 51:566-75.
40. Lewis M, Simpson P. Francen S, Huang W, Whitcomb J, Mosley M. CXCR4-using virus detected in patients receiving maraviroc in the phase III studies MOTIVATE 1 and 2 originates from a pre-existing minority of CXCR4-using virus. 16th International HIV Drug Resistance Workshop, Barbados, West Indies, June 2007;56 [abstract].
41. Lalezari J, Goodrich J, DeJesus E, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24-week results of a phase 2b/ 3 Study in the USA and Canada. 14th CROI, Los Angeles, California, USA, February 2007;104bLB [abstract].
42. Mayer H, Van der Ryst E, Saag M, et al. Safety and efficacy of maraviroc, a novel CCR5 antagonist, when used in combination with optimized background therapy for the treatment of antiretroviral-experiences subjects infected with dual/mixed-tropic HIV-1: 24-week results of a phase 2b exploratory trial. XVI International AIDS Conference, Toronto, Canada, August 2006;THLB0215 [abstract].
43. Nelson M, Fäatkenheuer G, Konourina I, et al. Efficacy and safety of maraviroc plus optimized background therapy in viremic, ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia, and North America: 24-week results. 14th CROI, Los Angeles, USA, February 2007;104aLB [abstract].
44. Skrabal K. Low A, Dong W, et al. Determining HIV coreceptor use in a clinical setting: Degree of correlation between two phenotypic assays and a boinformatic model. J Clin Microbiol. 2007;45:279-84.
45. Reeves J. Han D, Liu Y. et al. Enhancements to the Trofile HIV Coreceptor Tropism Assay enable reliable detection of CXCR4-using subpopulations at less than 1%, 47th ICAAC. Chicago, USA, September 2007;H-1026 [abstract].
46. Trinh L, Han D, Huang W, et al, Technical validation of an enhanced sensitivity Trofile HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5. Antiviral Therapy. 2008;13(Suppl 3):A128 [abstract].
47. Su Z, Reeves J, Krambrink A, et al. Response to vicriviroc in HIV-infected, treatment experienced individuals using an enhanced version of the Trofile HIV coreceptor tropism assay [Trofile (ES)]: reanalysis of ACTG 5211 results. Antiviral Therapy. 2008;13(Suppl 3):A98 [abstract].
48. Cheng-Mayer C, Quiroga M. Tung J, Dina D, Levy J. Viral determinants of HIV-1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol. 1990;64:4390-8.
49. de Jong J, Goudsmit J, Keulen W, et al. HIV-1 clones chimeric for the envelope V3 domain differ in syncytium formation and replication capacity. J Virol. 1992;66:757-65.
50. O'Brien W, Koyanagi Y, Namazie A. et al. HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature. 1990;348:69-73.
51. Shioda T, Levy J, Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined byspecific regionsofthe envelope gp120 gene. Nature, 1991;349:167-9.
52. Westervelt P, Trowbridge D, Epstein L, et al. Macrophage tropism determinants of HIV-1 in vivo. J Virol, 1992;66:2577-82.
53. Lamers S, Sleasman J, She J, et al. Persistence of multiple maternal genotypes of HIV-1 in infants infected by vertical transmission. J Clin Invest. 1994;93:380-90.
54. De Jong J, De Ronde A, Keulen W, Tersmette M, Goudsmit J. Minimal requirements for the HIV-1 V3 domain to support the syncytium-inducing phenotype: Analysis by single amino acid substitution. J Virol. 1992;66:6777-80.
55. Freed E, Myers D, Risser R. Identification of the principal neutralizing determinant of HIV-1 as a fusion domain. J Virol. 1991; 65:190-4.
56. Todd B, Kedar P, Pope J. Syncytium induction in primary CD4+ T-cell lines from normal donors by HIV-1 isolates with non-syncytium-inducing genotype and phenotype in MT-2 cells. J Virol. 1995;69:7099-105.
57. Moore J, McCutchan F, Poon S, et al. Exploration of antigenic variation in gp120 from clades A through F of HIV-1 by using monoclonal antibodies. J Virol. 1994;68:8350-64.
58. Fouchier R, Brouwer M, Broersen S, Schuitemaker H. Simple determination of HIV-1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol. 1995;33:906-11.
59. Jensen M, van 't Wout A. Predicting HIV-1 coreceptor usage with sequence analysis. AIDS Rev. 2003;5:104-12.
60. Brumme Z, Goodrich J, Mayer H, et al. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis. 2005;192:466-74.
61. Resch A Hoffman N, Swanstrom R. Improved success of phenotype prediction of the HIV-1 from envelope variable loop 3 sequence using neural networks. Virology. 2001;288:51-62.
62. Brumme Z, Dong W, Yip B, et al. Clinical and immunologic impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS. 2004;18:F1-9.
63. Edgar R. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 2004;32:1792-7.
64. Poveda E, Seclen E, Gonzalez M, et al. Improvement of genotypic algorithms to predict HIV-1 tropism in treatment-experienced patients - correlation with Trofile results. Antiviral Therapy, 2008;13 (Suppl 3):A109 [abstract].
65. Shioda T, Levy J, Cheng-Mayer C. Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature. 1991;349:167-9.
66. Chesebro B, Wehrly K, Nishio J, Perryman S. Mapping of independent V3 envelope determinants of HIV-1 macrophage tropism and syncytium formation in lymphocytes. J Virol. 1996;70:9055-9.
67. Lee M, Heaton J, Cho M. Identification of determinants of interaction between CXCR4 and gp120 of adual-tropic HIV-1DH12 isolate. Virology. 1999;257:290-6.
68. Smyth R, Yi Y, Singh A, Collman R. Determinants of entry cofactor utilization and tropism in a dual-tropic HIV-1 primary isolate. J Virol. 1998;72:4478-84.
69. Labrosse B, Treboute C, Brelot A. Alizon M. Cooperation of the V1/V2 and V3 domains of HIV-1 gp120 for interaction with the CXCR4 receptor. J Virol. 2001;75:5457-64.
70. Briggs D, Tuttle D, Sleasman J, Goodenow M. Envelope V3 amino acid sequence predicts HIV-1 phenotype (coreceptor usage and tropism for macrophages). AIDS. 2000;14:2937-9.
71. Jensen M, Li F, van 't Wout A, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of HIV-1 env V3 loop sequences. J Virol, 2003;77:13376-88.
72. Pillai S, Good B, Richman D, Corbel J, A new perspective on V3 phenotype prediction. AIDS Res Hum Retroviruses. 2003;19:145-9.
73. Sing T, Lengauer T, Beerenwinkel N, et al. Immunologic and virologic parameters improve genotypic prediction of HIV-1 coreceptor usage. 1st Int. Workshop on Targeting HIV Entry, Bethesda, USA, December, 2000 [abstract 30].
74. Moores A, Thielen A, Dong W, et al. Improved detection of X4 virus by V3 genotyping: application to plasma RNA and proviral DNA. Antiviral Therapy. 2008;13(Suppl 3):A99 [abstract].
75. Giulieri S, Knoepfel S, Rauch P, Gunthard H, Cavassini M, Metzner K. Minority quasispecies of drug-resistant HIV-1 leading to early therapy failure in treatment-naïve and adherent patients. Antiviral Therapy. 2008;13(Suppl 3):A116 [abstract].
76. Chueca N, Martin L, Alvarez M, et al. A combination of bioinformatics tools can be accurately used for the screening of coreceptor usage in clinical samples. Antiviral Therapy. 2008;13(Suppl 3):A106 [abstract].
77. Obermeier M, Sichtig N, Braun P, et al. Determination of HIV-1 coreceptor usage in German patients - comparison of genotypic methods with the TROFILE phenotypic assay. Antiviral Therapy. 2008;13(Suppl 3): A112 [abstract].
78. Recordon-Pinson P, Soule C, Anies G, et al. Evaluation of the genotypic prediction of HIV-1 coreceptor tropism in a clinical setting. Antiviral Therapy. 2008;13(Suppl 3):A113 [abstract].
79. Sander O, Sing T, Sommer I, et al, Structural descriptors of gp120 V3 loop for the prediction of HIV-1 coreceptor usage. PLoS Comput Biol. 2007;3:e58.
80. Thelen A, Harrigan P, Low A, et al. Improved prediction of HIV-1 coreceptor usage by incorporating V2 loop sequence variation. Antiviral Therapy. 2008;13(Suppl 3:A113 [abstract].
81. Daumer M, Kaiser R, Klein R, Lengauer T, Thiele B, Thelen A. Inferring viral tropism from genotype with massively parallel sequencing: qualitative and quantitative analysis. Antiviral Therapy. 2008;13(Suppl 3):A101 [abstract].
82. Tsibris A, Arnaout R, Korber B, et al. Dynamic HIV-1 escape from vicriviroc therapy in vivo, Antiviral Therapy. 2008;13(Suppl 3):A97 [abstract].
83. Maeda K, Nakata H, Ogata H, Koh Y, Myakawa T, Mitsuya H. The current status of and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. Curr Opin Pharmacol. 2004; 4:447-52.
84. Seibert C, Sakmar T. Small-molecule antagonists of CCR5 and CXCR4: A promising new class of anti-HIV-1 drugs. Curr Pharm Des. 2004; 10:2041-62.
85. Westloy M. van der Ryst E, CCR5 antagonists: Host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chernother. 2005; 16:339-54.
86. Strizki J, Tremblay C, Xu S, et al. Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against HIV-1. Antimicrob Agents Chemother. 2005;49:4911-19.
87. Larder B, Kohli A, Kellam P, Kemp S, Kronick M, Henfrey R. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature. 1993;365:671-3.
88. Leitner T, Halapi E, Scarlatti G, et al. Analysis of heterogeneous viral populations by direct DNA sequencing. BioTechniques. 1993; 15:120-7.
89. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the HIV-1 reverse transcriptase. J Clin Microbiol. 1999;37:2291-6.
90. Van Laethem K, Van Vaerenbergh K, Schmit J, et al. Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr. 1999;22:107-18.
91. Labernardiere J, Lebel-Binay S, Faudo J, Holguin A, Soriano V, Cheret A. Tropism determination and performance of Phenoscript™ HIV-1 entry inhibitor assay. Antiviral Therapy 2005;9:S141 [abstract].
92. Pathway Diagnostics. Pathway Diagnostics Announces Commercial Availability of SensiTrop™ HIV Co-receptor Tropism Assay. Malibu, California: Pathway Diagnostics, 2007.
93. Delwart E, Gordon C. Tracking changes in HIV-1 envelope quasispecies using DNA heteroduplex analysis. Methods. 1997; 12:348-54.
94. Nelson J, Fiscus S, Swanstrom R. Evolutionary variants of the HIV-1 V3 region characterized by using a heteroduplex tracking assay. J Virol. 1997;71:8750-8.
95. Nelson J, Baribaud F, Edwards T, Swanstrom R. Patterns of changes in HIV-1 V3 sequence populations late in infection. J Virol. 2000; 74:8494-501.
96. Coetzer M, Cilliers T, Ping L, Swanstrom R, Morris L. Genetic I characteristics of the V3 region associated with CXCR4 usage in HIV-1 subtype C isolates. Virology. 2006;356:95-105.
97. Hamy F, Garcia O, Klimkait T. Coreceptor tropism of HIV in clinical sample dissected by rPhenotyping. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia, July 2007 [abstract 009].
98. Li W, Webb E, Nary L, Robins T. SensiTrop QT: A novel molecular diagnostic assay for the detection and quantification of HIV coreceptor tropism. 15th CROI, Boston, USA, Feb 2008 [abstract 919].
99. Tressler R. Valdex H, van der Ryst E, et al. Comparison ol results from the SensiTrop vs. Trofile assays on 100 samples from the maraviroc expanded access program. 15th CROI, Boston, USA, Feb 2008 [abstract 920].
100. Merriweather A. Study Reaffirms Superiority of Trofile (TM) Assay . Accessed 01/13/2008, Reuters, UK.
101. Invirion Diagnostics. Virotect Tropism Assay for HIV-1 . Accessed 01/7/2008. Invirion Diagnostics, LLC, Oak Brook, IL, 2007.
102. Delobel P, Sandres-Sauné K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective HAART. J Acquir Immune Defic Syndr. 2005;38:382-92.
103. Verhofstede C, Vanderkerckhove L, Van Eygen V, et al. CXCR4-using strains are actually more abundant in PBMC than in plasma RNA. 6th European HIV Drug Resistance Workshop, Budapest Hungary. March 2008 [abstract].
104. Mosier D, Picchio G, Gulzia R. et al. Highly potent RANTES analogues either prevent CCR5-using HIV-1 infection in vivo or rapidly select for CXCR4-using variants. J Virol. 1999;73:3544-50.
105. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia growth and development study. multicenter AIDS cohort study, multicenter hemophilia cohort study, San Francisco city cohort, ALIVE study. Science. 1996; 273:1856-62.
106. Eugen-Olsen J, Iversen A, Garred P, et al. Heterozygosity for a deletion in the CKR-5 gene leads to prolonged AIDS-free survival and slower CD4 T-cell decline in a cohort of HIV-seropositive individuals. AIDS. 1997;11:305-10.
107. Wu L, Paxton W, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1 in vitro, J Exp Med. 1997;185:1681-91.
108. Benkirane M, Jin D, Chun R, Koup R, Jeang K. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem. 1997;272:30603-6.
109. D'Aquila R, Sutton L. Savara A, Hughes M, Johnson V. CCR5/delta(ccr5) heterozygosity: A selective pressure for the syncytium-inducing HIV-1 phenotype. NIAID AIDS clinical trials group protocol 241 virology team. J Infect Dis. 1998;177:1549-53.
110. Zhang L, He T, Huang Y, et al. Chemokine coreceptor usage by diverse primary isolates of HIV-1. J Virol. 1998;72:9307-12.
111. T cells, are associated with R5-to-X4 HlV type 1 virus evolution. AIDS Res Hum Retroviruses. 2003;19:389-98.
112. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc; utilize inhibitor-bound receptor for entry. J Virol. 2007;81:2359-71.
113. Kuhmann S, Pugach P, Kunstman K, et al. Genetic and phenotypic analyses of HIV-1 escape from a small-molecule CCR5 inhibitor. J Virol. 2004;78:2790-807.
114. Trkola A, Kuhmann S, Strizki J, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA. 2002;99:395-400.
115. Pugach P, Marozsan A, Ketas T, Landes E, Moore J, Kuhmann S. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology. 2007;361:212-28.
116. Wei J, Hogan P, Paulman R. et al. In vitro selection and characterization of maraviroc-resistant HIV-1. Antiviral Therapy. 2008;13(Suppl3):A64 [abstract].
117. Howe J, Murgolo N, Hou Y, et al. Defining the structural and functional roles of mutations in gp120 associated with the emergence of HIV-1 clinical resistance to the CCR5 antagonist vicriviroc. Antiviral Therapy. 2008;13(Suppl 3):A36 [abstract].
118. Anastassopoulou C, Marozsan A, Matet A, et al. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss. PLoS Pathog. 2007;3:e79.
119. Huang W, Wojcik L, Toma J, et al. Escape of HIV-1 from a CCR5 antagonist can reduce envelope-mediated entry. Antiviral Therapy. 2008;13(Suppl 3):A65 [abstract].
120. Westby M. Lewis M, Whitcomb J, et al. Emergence of CXCR4-using HIV-1 variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol. 2006;80:4909-20.
121. van't Wout A, Coakley E, Reeves J, Petropoulos C, Schuitemaker H, Huang W. Dynamics of emergence of CXCR4-using HIV in clinical samples as detected by Trofile and MT-2 assays. Antiviral Therapy. 2008;13(Suppl 3):A93 [abstract].